Capital Analysts, LLC
Position in APLS — Apellis Pharmaceuticals, Inc.
CIK 1624758
FORT WASHINGTON, PA
Position in APLS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
57
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capital Analysts, LLC holds $605,272 across 14 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
650 | $405,301 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
119 | $59,110 | |
| 3 | FTRE |
Fortrea Holdings Inc.
|
2,661 | $46,301 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
446 | $25,520 | |
| 5 | MRNA |
Moderna, Inc.
|
163 | $11,414 | |
| 6 | SPRY |
ARS Pharmaceuticals, Inc.
|
1,300 | $10,413 | |
| 7 | OMER |
Omeros Corp
|
1,000 | $9,510 | |
| 8 | VRCA |
Verrica Pharmaceuticals Inc.
|
1,500 | $9,180 |
All Filings in APLS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 57 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | — | 57 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | — | 57 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | — | 57 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | — | 57 | Shares | Defined | 2025-05-14 | |
| 2021-12-31 | — | 57 | Shares | Defined | 2022-02-10 | |
| No filing history on record for this holder in this stock. | ||||||